Overview of cellular immunotherapy for patients with glioblastoma.

Abstract : High grade gliomas (HGG) including glioblastomas (GBM) are the most common and devastating primary brain tumours. Despite important progresses in GBM treatment that currently includes surgery combined to radio- and chemotherapy, GBM patients' prognosis remains very poor. Immunotherapy is one of the new promising therapeutic approaches that can specifically target tumour cells. Such an approach could also maintain long term antitumour responses without inducing neurologic defects. Since the past 25 years, adoptive and active immunotherapies using lymphokine-activated killer cells, cytotoxic T cells, tumour-infiltrating lymphocytes, autologous tumour cells, and dendritic cells have been tested in phase I/II clinical trials with HGG patients. This paper inventories these cellular immunotherapeutic strategies and discusses their efficacy, limits, and future perspectives for optimizing the treatment to achieve clinical benefits for GBM patients.
Type de document :
Article dans une revue
Clinical and Developmental Immunology, Hindawi Publishing Corporation, 2010, 2010, pp.689171. 〈10.1155/2010/689171〉
Liste complète des métadonnées

Littérature citée [142 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-00532866
Contributeur : Hervé De Villemeur <>
Soumis le : jeudi 4 novembre 2010 - 15:52:51
Dernière modification le : mercredi 16 mai 2018 - 11:22:33
Document(s) archivé(s) le : samedi 5 février 2011 - 03:03:03

Fichier

689171.pdf
Fichiers éditeurs autorisés sur une archive ouverte

Identifiants

Citation

Elodie Vauléon, Tony Avril, Brigitte Collet, Jean Mosser, Véronique Quillien. Overview of cellular immunotherapy for patients with glioblastoma.. Clinical and Developmental Immunology, Hindawi Publishing Corporation, 2010, 2010, pp.689171. 〈10.1155/2010/689171〉. 〈inserm-00532866〉

Partager

Métriques

Consultations de la notice

292

Téléchargements de fichiers

280